{"id":126192,"date":"2025-10-16T16:42:16","date_gmt":"2025-10-16T16:42:16","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/126192\/"},"modified":"2025-10-16T16:42:16","modified_gmt":"2025-10-16T16:42:16","slug":"gynecology-drugs-market-size-to-reach-usd-112-6-billion-by-2034-rising-gynecological-disorders-and-health-awareness-drive-market-growth","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/126192\/","title":{"rendered":"Gynecology Drugs Market Size to Reach USD 112.6 Billion by 2034 Rising Gynecological Disorders and Health Awareness Drive Market Growth"},"content":{"rendered":"

<\/p>\n

According to Statifacts, the worldwide gynecology drugs
\nmarket size was valued at approximately USD 69.79 billion in 2024 and is estimated
\nto hit around USD <\/b>97.55 billion by 2031. The gynecology drugs market is driven by the increasing consumer
\npreference towards treatments that enhance immunity systems and overall health and wellness<\/b><\/a>.<\/p>\n

<\/p>\n

This report is readily available for
\nimmediate delivery. We can review it with you in a meeting to ensure data
\nreliability and quality for decision-making.<\/b><\/p>\n

Try Before You Buy \u2013 Get the Sample Report@ <\/b>https:\/\/www.statifacts.com\/stats\/databook-download\/8061<\/b><\/a>\n<\/p>\n

Gynecology Drugs Market
\nHighlights<\/b><\/p>\n

\u2022 North America led the global gynecology drugs market in 2024.
\nMeanwhile, the Asia Pacific region is expected to experience the highest growth
\nrate throughout the forecast period.<\/p>\n

\u2022 Europe witnessed significant growth in the gynecology drugs market
\nin 2024, contributing to the global market expansion.<\/p>\n

\u2022 By therapeutic insights, the non-hormonal therapy segment
\ndominated the market in 2024. However, the hormonal therapy segment is
\nforecasted to grow at the fastest pace between 2025 and 2034.<\/p>\n

\u2022 By indication trends, the contraception (birth control) was the
\nleading indication in 2024. The menopausal disorder segment is anticipated to
\nregister the highest growth rate during the period from 2025 to 2034.<\/p>\n

\u2022 By distribution channels, the hospital pharmacies held the largest
\nmarket share in 2024. However, the retail pharmacies segment is predicted to
\nsee the highest compound annual growth rate (CAGR) during the study period.<\/p>\n

Market Outlook and
\nIndustry Potential<\/b><\/p>\n

The gynecology drugs market is attributed to the rising adoption
\nof medicine for diseases including chronic disorders and cancer, increasing demand
\nfor advanced treatments such as gynecology checkpoint inhibitors and CAR T-cell therapies<\/b><\/a>, increasing patient
\nconsciousness of biosimilars and monoclonal antibodies<\/b><\/a>, growing geriatric population
\nand rising technological advancements in research and development activities.<\/p>\n

In addition, the significant opportunities in the global market
\nare rising diversification and product development and rising technological
\nadvancements. By enabling more convenient, effective and efficient treatments and
\nservices, the rise of innovation can increase demand for gynecology drugs. The gynecology
\ndrug therapy of product development launching new ones and improving existing
\nproducts to increase consumer demands, which further transform the growth of
\nthe gynecology drugs market in the coming years.<\/p>\n

Latest Trends in Gynecology Drugs Market:<\/b><\/p>\n\n\n

Category<\/b><\/p>\n<\/td>\n\n

Details<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

\u00a0Global
\n Market Trends<\/b><\/p>\n<\/td>\n\n

– Shift
\n toward non-hormonal therapies<\/b> for menopause and endometriosis. –
\n Rising demand for long-acting reversible contraceptives (LARCs)<\/b>. – Growth
\n in combination therapies<\/b> targeting multiple gynecological conditions.
\n – Digital health integration<\/b> (telemedicine + prescription platforms)
\n expanding access to gynecology drugs.<\/p>\n<\/td>\n<\/tr>\n\n\n

\u00a0Therapeutic
\n Focus Areas<\/b><\/p>\n<\/td>\n\n

– Endometriosis
\n & Fibroids<\/b>: Increased development of GnRH antagonists (e.g.,
\n elagolix, relugolix). – PCOS<\/b>: Research into metabolic and
\n anti-inflammatory therapies. – Menopause<\/b>: Development of safer hormone
\n therapies and SERMs (Selective Estrogen Receptor Modulators). – Infertility
\n & IVF Adjuncts<\/b>: Rising support drug demand with IVF cycle growth.<\/p>\n<\/td>\n<\/tr>\n\n\n

\u00a0Growth
\n Drivers<\/b><\/p>\n<\/td>\n\n

– Growing
\n prevalence of reproductive health disorders<\/b>. – Higher awareness and early
\n diagnosis<\/b> of gynecological conditions. – Increase in delayed
\n pregnancies<\/b>, boosting demand for fertility treatments. – Rising
\n government women\u2019s health initiatives<\/b> in emerging markets.<\/p>\n<\/td>\n<\/tr>\n\n\n

\u00a0Innovation
\n & R&D<\/b><\/p>\n<\/td>\n\n

– Focus on targeted
\n therapies<\/b> and personalized medicine<\/b> for gynecology. – Biologics<\/b>
\n and monoclonal antibodies<\/b> under development for gynecologic cancers. –
\n Use of AI in drug discovery<\/b> and patient-specific treatment matching.<\/p>\n<\/td>\n<\/tr>\n\n\n

\u00a0Emerging
\n Country Highlight<\/b><\/p>\n<\/td>\n\n

India<\/b> is a key emerging
\n player: – Rapid urbanization, rising awareness, and expanding health
\n insurance are increasing access to gynecology care. – Government programs
\n like Mission Shakti<\/b> and Ayushman Bharat<\/b> support women’s health.
\n – Domestic pharma companies are expanding generic and branded gynecology drug
\n portfolios.<\/p>\n<\/td>\n<\/tr>\n\n\n

\u00a0Market
\n Access Challenges<\/b><\/p>\n<\/td>\n\n

– Pricing
\n pressures in public health systems (especially in Asia, Africa). – Cultural
\n taboos and stigma<\/b> still limit access in some regions. – Regulatory
\n disparities between countries slowing cross-border drug approval.<\/p>\n<\/td>\n<\/tr>\n

\nKindly
\nuse the following link to access our scheduled meeting@ <\/b>https:\/\/www.statifacts.com\/schedule-meeting<\/b><\/a><\/p>\n

AI Impact on Gynecology Drugs Market<\/b><\/p>\n

AI is revolutionizing the global market revenue by adopting
\nseveral technological advancements. By detecting huge clinical datasets, AI is revolutionizing the
\ngynecology industry. It is also revolutionizing personalized treatment
\nstrategies, development of gynecology drugs and drug discovery<\/b><\/a> across several
\ndiseases. AI can also improve therapeutic approaches and detect outcomes
\nsignificantly and continuously by identifying intricate patterns. <\/p>\n

In addition, AI is having major impact on the gynecology drugs
\nindustry, enhancing the personalization, convenience and speed of treatment.
\nLeading to
\nmore targeted and efficient medical therapies, researchers can better
\nunderstand the complicated connections between the cancer and immune system, by
\nleveraging AI for drug data analysis, which further expected to transform the
\ngrowth of the gynecology drugs market in the coming years.<\/p>\n

Case Study: AI-Driven Drug Discovery Accelerating Innovation in
\nWomen\u2019s Health<\/b><\/p>\n

<\/p>\n

Background:<\/b><\/p>\n

In recent years, artificial intelligence<\/b><\/a> (AI) has become a
\ncornerstone of pharmaceutical innovation<\/b><\/a>, particularly in
\nwomen\u2019s health. The global gynecology drugs market, projected to reach USD
\n112.6 billion by 2034, is increasingly influenced by AI\u2019s transformative
\npotential in accelerating drug discovery and personalized therapies. With
\nrising incidences of disorders like PCOS, endometriosis, and menopause-related
\nconditions, pharmaceutical companies are seeking faster, cost-effective, and
\nprecision-based solutions to develop next-generation gynecological drugs.<\/p>\n

A notable development in this space occurred in October 2025,
\nwhen Takeda Pharmaceutical and Nabla Bio announced an expansion of their
\nAI-powered biologics design collaboration using Nabla\u2019s proprietary Joint
\nAtomic Model (JAM) platform. This model leverages generative AI to identify,
\ndesign, and optimize therapeutic proteins, dramatically reducing discovery time
\nand cost. Although primarily focused on immunology and oncology<\/b><\/a>, the framework
\ndemonstrates strong potential to revolutionize gynecology-focused drug
\ndiscovery as well.<\/p>\n

Challenge:<\/b><\/p>\n

Traditional gynecology drug development faces several
\nbottlenecks:<\/p>\n

\u2022
\nHigh
\nR&D costs and lengthy clinical trials<\/b>, particularly for hormonal therapies.<\/p>\n

\u2022
\nComplexity
\nof female hormonal pathways<\/b> that vary significantly across individuals.<\/p>\n

\u2022
\nLimited
\nfocus on non-hormonal therapies<\/b>, despite increasing patient demand for safer alternatives.<\/p>\n

\u2022
\nUnderrepresentation
\nof women<\/b>
\nin clinical research, slowing innovation and evidence generation.<\/p>\n

These limitations have resulted in slow market introduction for
\ninnovative therapies targeting menopause, infertility, and gynecological
\ncancers creating a gap that AI and machine learning<\/b><\/a> technologies are now
\nbeginning to fill.<\/p>\n

Objective:<\/b><\/p>\n

The primary objective was to evaluate how AI can:<\/p>\n

\u2022
\nReduce the time-to-market<\/b>
\nfor new gynecology drugs.<\/p>\n

\u2022
\nEnhance precision
\nand personalization<\/b> in drug targeting.<\/p>\n

\u2022
\nSupport data-driven
\nR&D decisions<\/b> through predictive modeling and biomarker identification.<\/p>\n

Enable scalable innovation in emerging markets<\/b> such as
\nIndia and Southeast Asia, where women\u2019s health needs are expanding rapidly.<\/p>\n

Approach:<\/b><\/p>\n

Takeda and Nabla Bio\u2019s collaboration provided a real-world
\nframework adaptable to gynecological drug discovery:<\/p>\n

\u2022
\nAI-Based
\nMolecular Design<\/b>: Nabla\u2019s JAM platform simulates protein ligand interactions
\nwith atomic precision, allowing researchers to identify potential compounds
\neffective against estrogen receptors or inflammatory pathways implicated in
\nendometriosis and PCOS.<\/p>\n

\u2022
\nGenerative
\nDrug Modeling<\/b>: Using generative algorithms, the platform produces thousands
\nof potential drug candidates, rapidly filtering those with optimal safety and
\nefficacy profiles.<\/p>\n

\u2022
\nPredictive
\nAnalytics for Patient Outcomes<\/b>: AI models can predict how different hormonal or non-hormonal
\ncompounds perform across varied patient demographics an essential step for
\nprecision medicine in women\u2019s health.<\/p>\n

\u2022
\nClinical
\nTrial Optimization:<\/b> Machine learning aids in patient stratification, improving
\nrecruitment efficiency and trial success rates for gynecological drugs.<\/p>\n

By integrating this AI-driven discovery approach into
\ngynecology-focused pipelines, pharmaceutical firms could potentially shorten
\ndrug discovery timelines from 5\u20137 years to under 3 years, while significantly
\ncutting early-stage costs.<\/p>\n

Implementation:<\/b><\/p>\n

The case study illustrates a scalable adaptation model:<\/p>\n

\u2022
\nPhase 1
\n(Feasibility & Data Integration)<\/b>: Pharmaceutical R&D teams integrate gynecology-specific
\nbiological datasets \u2014 such as hormone receptor structures, patient genomics,
\nand disease biomarkers \u2014 into the AI system.<\/p>\n

\u2022
\nPhase 2
\n(Algorithm Training)<\/b>: The AI is trained to identify patterns linked to gynecological
\ndiseases, including molecular triggers in PCOS, endometriosis, or fibroids.<\/p>\n

\u2022
\nPhase 3
\n(Candidate Generation)<\/b>: Using generative design, AI models create new compounds that
\nmimic or block hormonal actions, focusing on safety, stability, and efficacy.<\/p>\n

\u2022
\nPhase 4
\n(Validation & Clinical Simulation)<\/b>: The platform runs simulations to predict real-world
\ntherapeutic outcomes, helping prioritize the most promising candidates for
\npreclinical trials.<\/p>\n

Results:<\/b><\/p>\n

While the Takeda\u2013Nabla collaboration\u2019s initial targets are
\nbeyond gynecology, the results validate AI\u2019s transformative role in
\npharmaceutical development:<\/p>\n

\u2022
\nReduction
\nin molecule screening<\/b> time by 60\u201370%.<\/p>\n

\u2022
\nImproved
\ncandidate success rates<\/b> due to precise target prediction.<\/p>\n

\u2022
\nEnhanced
\npersonalization potential<\/b>, particularly valuable for conditions like menopause and PCOS,
\nwhere treatment responses vary widely among women.<\/p>\n

When applied to gynecology, similar outcomes could accelerate
\ndevelopment of safer non-hormonal therapies and targeted biologics for chronic
\nreproductive disorders.<\/p>\n

These advancements align with market dynamics highlighted in
\nStatifacts\u2019 press release especially the shift toward non-hormonal therapies,
\ngrowing AI integration, and expansion in emerging regions such as India and
\nAsia-Pacific.<\/p>\n

Impact:<\/b><\/p>\n

The integration of AI into gynecology drug discovery presents a
\nparadigm shift:<\/p>\n

\u2022
\nEconomic
\nImpact:<\/b>
\nPotential reduction of R&D expenditure by 40\u201350%, enhancing affordability
\nand scalability.<\/p>\n

\u2022
\nClinical
\nImpact:<\/b>
\nFaster availability of personalized, side-effect-minimized drugs.<\/p>\n

\u2022
\nStrategic
\nImpact:<\/b>
\nStrengthened collaborations between global pharma companies, AI startups, and
\nresearch institutions focused on women\u2019s health equity.<\/p>\n

For instance, India\u2019s domestic firms like Emcure
\nPharmaceuticals, already expanding into the menopause and PCOS segment, could
\nleverage AI models to advance their pipelines and compete globally<\/p>\n

Shape the insights, trends and
\nstrategic planning your way 50% customization is on us!<\/b><\/p>\n

Customize This
\nStudy as Per Your Requirement@ <\/b>https:\/\/www.statifacts.com\/stats\/customization\/8061<\/b><\/a> <\/b><\/p>\n

Market Challenge<\/b><\/p>\n

Strict Regulatory Approvals<\/b><\/p>\n

One of the major challenging factors restraining the market
\ngrowth is the commercializing and developing immunotherapy drug<\/b><\/a>. Due to these
\nexhaustive demands small-scale companies face major issues. In addition,
\nincreasing prevalence of drug resistance, high cost of gynecology drug clinical trials<\/b><\/a>, and increase of complicated
\nmanufacturing of drugs are the major retraining factors which are expected to hinder
\nthe growth of the gynecology drugs market.<\/p>\n

Global Government Initiatives Supporting the Gynecology Drugs
\nMarket<\/b><\/p>\n

United
\nStates<\/b><\/p>\n

\u2022 White
\nHouse Initiative on Women\u2019s Health Research<\/strong>
A national program boosting funding and innovation in under-researched areas
\nlike menopause, endometriosis, and PCOS.<\/p>\n

\u00a0United Kingdom<\/strong><\/p>\n

\u2022 Women\u2019s
\nHealth Strategy for England (2022\u20132030)<\/strong>
Focused on improving access to gynecology
\nservices, menopause care<\/strong>,<\/b> and closing gender health
\ngaps through NHS reforms.<\/p>\n

Germany<\/strong><\/p>\n

\u2022 BMG
\nWomen\u2019s Health Research Fund<\/strong>
<\/b>Germany\u2019s
\nFederal Ministry of Health supports academic and clinical research into gynecological diseases and reproductive health<\/strong>.<\/b><\/p>\n

\u00a0<\/b>France<\/strong><\/p>\n

\u2022 French
\nNational Health Strategy \u2013 Focus on Women\u2019s Rights<\/strong>
Government backing for affordable access to contraceptives, fertility
\ntreatments<\/strong>,<\/b> and women-centered drug development.<\/p>\n

Canada<\/strong><\/p>\n

\u2022 Women\u2019s
\nHealth Initiative \u2013 Canadian Institutes of Health Research (CIHR)<\/strong>
<\/b>Provides
\nfunding for research on female-specific health issues<\/strong>,<\/b> including
\nhormonal and gynecological disorders.<\/p>\n

\u00a0<\/b>Japan<\/strong><\/p>\n

\u2022 Women\u2019s
\nHealth Promotion Act<\/strong>
<\/b>National
\nstrategy focusing on aging, reproductive health<\/strong>, and improved
\naccess to hormonal therapies and gynecology drugs<\/strong>.<\/p>\n

Gynecology Drugs Market Regional Insights:<\/b><\/p>\n

What has Made North
\nAmerica the Leader in Industry in Recent Years?<\/b><\/p>\n

North America dominated the gynecology drugs market revenue in
\n2024. The market growth in the region is driven by factors such as the increasing
\nexpansion of insurance coverage and healthcare services, rising investments in
\nresearch and development activities, increasing presence of leading
\npharmaceutical companies, high health spendings and well-developed healthcare infrastructure.
\nThe U.S. and Canada are dominating countries driving the market growth. <\/p>\n

United States: Growth Drivers in the Gynecology Drugs Market<\/strong><\/p>\n

\u2022 High Prevalence of
\nGynecological Conditions<\/strong>
Conditions like endometriosis, uterine fibroids, menopause symptoms<\/strong>, and PCOS<\/strong> affect
\nmillions of U.S. women, driving strong demand for targeted therapies.<\/p>\n

\u2022 Advanced R&D and
\nInnovation Hub<\/strong>
The U.S. leads in the development of non-hormonal therapies,
\nlong-acting contraceptives, and biologics<\/strong> for gynecologic disorders
\nand cancers.<\/p>\n

\u2022 Strong Focus on Women\u2019s
\nHealth Equity<\/strong>
Federal initiatives and funding (e.g., White House Women\u2019s Health
\nResearch Agenda<\/strong>) are prioritizing underserved areas of gynecology drug
\ndevelopment.<\/p>\n

\u2022 Expanding Menopause and
\nMidlife Health Market<\/strong>
Growing attention to menopausal care<\/strong>, including hormone replacement
\ntherapy (HRT)<\/strong> and SERMs<\/strong>, is boosting innovation and market expansion.<\/p>\n

\u2022 Integration of Digital
\nHealth & Femtech<\/strong>
Widespread use of women\u2019s health apps, wearables<\/strong>, and telehealth
\nplatforms<\/strong> is streamlining access to gynecology consultations and
\nprescriptions.<\/p>\n

Asia Pacific Gynecology Drugs Market Trends:<\/b><\/p>\n

Asia Pacific is expected to grow fastest during the forecast
\nperiod. The market growth in the region is attributed to factors such as the
\nincreasing investments in women\u2019s health initiatives, improving diagnosis rates
\nand expanding healthcare access. China, India, Japan and South Korea are the
\nfastest growing countries fueling the market growth.<\/p>\n

India: Growth Drivers in the
\nGynecology Drugs Market<\/b><\/p>\n

\u2022 Rising Prevalence of
\nWomen’s Health Disorders<\/b>
Increasing cases of PCOS, endometriosis, uterine fibroids<\/b>, and infertility<\/b>
\nare boosting demand for both prescription and OTC gynecology drugs.<\/p>\n

\u2022 Expanding Middle-Class
\n& Urban Population<\/b>
Greater awareness and health-seeking behavior in urban women are driving demand
\nfor contraceptives, hormonal therapies<\/b>, and fertility medications<\/b>.<\/p>\n

\u2022 Government-Backed Women\u2019s
\nHealth Programs<\/b>
Initiatives like Ayushman Bharat<\/b>, Janani Suraksha Yojana<\/b>, and Mission
\nShakti<\/b> are enhancing access to maternal and reproductive healthcare across
\nIndia.<\/p>\n

\u2022 Growing IVF & Fertility
\nServices Sector<\/b>
India’s booming IVF and ART (Assisted Reproductive Technology)<\/b> market is
\nleading to increased use of fertility support drugs<\/b>.<\/p>\n

Gynecology
\nDrugs Market Scope<\/b><\/p>\n\n\n

Report Attributes<\/b><\/p>\n<\/td>\n\n

Statistics<\/b><\/p>\n<\/td>\n<\/tr>\n\n\n

Market Size in 2024<\/p>\n<\/td>\n\n

USD 69.79 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market Size in 2025<\/p>\n<\/td>\n\n

USD 73.21 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market Size in 2030<\/p>\n<\/td>\n\n

USD 92.99 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market Size in 2032<\/p>\n<\/td>\n\n

USD 102.32 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

Market Size by 2034<\/p>\n<\/td>\n\n

USD
\n 112.6 Billion<\/p>\n<\/td>\n<\/tr>\n\n\n

CAGR
\n 2025-2034<\/p>\n<\/td>\n\n

4.9%<\/p>\n<\/td>\n<\/tr>\n\n\n

Leading
\n Region in 2024<\/p>\n<\/td>\n\n

North America<\/p>\n<\/td>\n<\/tr>\n\n\n

Fastest Growing Region<\/p>\n<\/td>\n\n

Asia Pacific<\/p>\n<\/td>\n<\/tr>\n\n\n

Base Year<\/p>\n<\/td>\n\n

2024<\/p>\n<\/td>\n<\/tr>\n\n\n

Forecast Years<\/p>\n<\/td>\n\n

2025-2034<\/p>\n<\/td>\n<\/tr>\n\n\n

Segments Covered<\/p>\n<\/td>\n\n

Therapeutics, Indication, Distribution Channel, and Region<\/p>\n<\/td>\n<\/tr>\n\n\n

Region Covered<\/p>\n<\/td>\n\n

North America, Europe, Asia Pacific, Latin America, Middle East
\n & Africa (MEA)<\/p>\n<\/td>\n<\/tr>\n\n\n

Key Players<\/p>\n<\/td>\n\n

Allergan plc, Amgen Inc., Bayer AG, Merck & Co., Inc., Pfizer
\n Inc., Eli Lilly Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Others.<\/p>\n<\/td>\n<\/tr>\n

Gynecology Drugs Market Segmentation
\nAnalysis<\/b><\/p>\n

Therapeutics<\/b> <\/b>Type Analysis<\/b><\/p>\n

The non-hormonal therapy segment dominated
\nthe gynecology drugs market revenue in 2024. The segment growth in the region
\nis driven by factors such as the increasing consumer preference towards
\nalternatives with less systemic side effects. These therapies are gaining
\npopularity in the mild gynecological infections and management of menopausal
\nsymptoms among women. <\/p>\n

The hormonal therapy segment is expected to
\ngrow fastest during the forecast period, due to its huge application in
\ntreating diseases such as contraception, menopause-related diseases and PCOS.
\nHormonal drugs are often expected first-line therapies due to their clinical familiarity,
\nfast symptom relief and proven efficacy.<\/p>\n

Indication Type Analysis<\/b><\/p>\n

Why Did the<\/b> Contraception
\nSegment Dominates the Gynecology Drugs Market Revenue in 2024?<\/b><\/p>\n

The contraception segment dominated the
\nglobal market revenue in 2024. Contraception helps in improving women’s health
\nand empowerment, preventing unintended pregnancies and addressing a fundamental
\nneed for family planning by reducing menstrual health issues, maternal
\nmortality and unsafe abortions.<\/p>\n

The menopausal disorder segment is expected
\nto grow fastest during the forecast period. The segment growth in the region is
\ndriven by the rising innovations in both non-hormonal and hormonal therapies,
\nincreasing patient awareness and growing geriatric female population.<\/p>\n

Distribution Channel Analysis<\/b><\/p>\n

The Hospital Pharmacies
\nSegment Dominates the Gynecology Drugs Market Revenue in 2024.<\/b><\/p>\n

The hospital pharmacies play an important
\nrole the global market, serving as major distribution channel, providing a crucial
\nsupply point for high-complexity, complex and specialized drugs requiring in-hospital
\nuse. They offer clinical expertise for specialized therapies, manage large and
\nspecialized drug inventories and ensure drug safety.<\/p>\n

The retail pharmacies segment is expected to
\ngrow fastest during the forecast period. Retail pharmacies offering
\npharmacist counselling for patient adherence and support and providing broad
\naccessibility for common medications.<\/p>\n

Browse
\nMore Research Reports:<\/b><\/p>\n

\u2022 The global gynecological devices
\nmarket size<\/b><\/a> surpassed USD 10.52 billion in 2024 and is predicted to reach
\naround USD 23.22 billion by 2034, registering a CAGR of 8.23% from 2025 to
\n2034.<\/p>\n

\u2022 The U.S. gynecological devices
\nmarket size<\/b><\/a> surpassed USD 3.85 billion in 2024 and is predicted to reach
\naround USD 8.53 billion by 2034, registering a CAGR of 8.28% from 2025 to 2034.<\/p>\n

\u2022 The laparoscopic gynecological
\nprocedures market size<\/b><\/a> is predicted to gain around USD 62.45
\nbillion by 2034 from USD 30.3 billion in 2024 with a CAGR of 7.5%.<\/p>\n

Ready to Dive Deeper? Visit Here to Buy Databook and In-depth
\nReport Now! <\/b>https:\/\/www.statifacts.com\/order-databook\/8061<\/b><\/a><\/p>\n

Top Companies in the
\nGynecology Drugs Market:<\/b><\/p>\n

\"A<\/b><\/p>\n

\u2022 Allergan plc<\/p>\n

\u2022 Amgen. Inc.<\/p>\n

\u2022 Bayer AG<\/p>\n

\u2022 Pfizer Inc.<\/p>\n

\u2022 AstraZeneca<\/p>\n

\u2022 Merck & Co., Inc.<\/p>\n

\u2022 Eli Lilly Company<\/p>\n

\u2022 F. Hoffmann-La Roche Ltd.\n<\/p>\n

Recent
\nDevelopments<\/b><\/p>\n

\u2022 In August 2025,<\/b> GlaxoSmithKline Pharmaceuticals marked its re-entry
\ninto the cancer drugs segment in the country and brought in Jemperli
\n(dostarlimab) and Zejula (niraparib) to India. The two oncology products
\nbrought at a \u201ctiered pricing\u201d for India, executives with the multinational
\ncompany said.<\/p>\n

\u2022 In May 2025, <\/b>Pune-headquartered Emcure Pharmaceuticals announced the expansion
\nof its gynaecology and dermatology product portfolio for the Indian market in
\nFY26 and launched a portfolio of products in the menopause and PCOS segment.<\/p>\n

Segments
\nCovered in the Report<\/b><\/p>\n

By Therapeutics<\/b><\/p>\n

\u2022 Hormonal Therapy<\/p>\n

o <\/b>Estrogen Therapy<\/p>\n

o <\/b>Progestin Therapy<\/p>\n

o <\/b>Combination Therapy<\/p>\n

o <\/b>Thyroid Replacement
\nTherapy<\/p>\n

o <\/b>Parathyroid Hormone
\nTherapy<\/p>\n

o <\/b>Others<\/p>\n

\u2022 Non-hormonal Therapy<\/p>\n

o <\/b>Anti-Infective Agents<\/p>\n

o <\/b>Anti-neoplastic Agents<\/p>\n

o <\/b>Anti-inflammatory Agents<\/p>\n

o <\/b>Others<\/p>\n

By Indication<\/b><\/p>\n

\u2022 Gynecological Cancers<\/p>\n

\u2022 Endometriosis<\/p>\n

\u2022 Female Infertility<\/p>\n

\u2022 Menopausal Disorder<\/p>\n

\u2022 Gynecology Infections<\/p>\n

\u2022 Polycystic Ovary Syndrome<\/p>\n

\u2022 Contraception (Birth Control)<\/p>\n

\u2022 Others<\/p>\n

By Distribution
\nChannel<\/b><\/p>\n

\u2022 Hospital Pharmacies<\/p>\n

\u2022 Retail Pharmacies<\/p>\n

\u2022 Online Pharmacies<\/p>\n

By Regions<\/b><\/p>\n

\u2022 North America<\/p>\n

o <\/b>U.S.<\/p>\n

o <\/b>Canada<\/p>\n

\u2022 Europe <\/p>\n

o <\/b>Germany<\/p>\n

o <\/b>UK<\/p>\n

o <\/b>France<\/p>\n

o <\/b>Italy<\/p>\n

o <\/b>Spain<\/p>\n

o <\/b>Sweden<\/p>\n

o <\/b>Denmark<\/p>\n

o <\/b>Norway<\/p>\n

\u2022 Asia Pacific <\/p>\n

o <\/b>China<\/p>\n

o <\/b>Japan<\/p>\n

o <\/b>India<\/p>\n

o <\/b>South Korea<\/p>\n

o <\/b>Thailand<\/p>\n

\u2022 Latin America <\/p>\n

o <\/b>Brazil<\/p>\n

o <\/b>Mexico<\/p>\n

o Argentina<\/p>\n

\u2022 Middle East and Africa (MEA) <\/p>\n

o <\/b>South Africa<\/p>\n

o UAE<\/p>\n

o Saudi Arabia<\/p>\n

o<\/a> Kuwait<\/p>\n

Ready
\nto Dive Deeper? Visit Here to Buy Databook and In-depth Report Now! <\/b>https:\/\/www.statifacts.com\/order-databook\/8061<\/b><\/a><\/p>\n

\ud835\udc00\ud835\udc1b\ud835\udc28\ud835\udc2e\ud835\udc2d \ud835\udc14\ud835\udc2c:<\/p>\n

Statifacts is a global
\nmarket intelligence and consulting leader, committed to delivering deep
\nstrategic insights that fuel innovation and transformation. With a sharp focus
\non the fast-evolving landscape of life sciences, we excel at navigating the
\nintricacies of cell and gene therapies<\/b><\/a>, oncology<\/b><\/a>, and drug
\ndevelopment. We empower our clients, ranging from biotech pioneers to
\ninstitutional investors with the intelligence needed to lead in high-impact
\nareas like regenerative medicine, cancer therapeutics, and precision health.
\nOur broad expertise across the pharma-biotech value chain is backed by robust,
\nstatistically driven data for every market we cover, ensuring decisions are
\ninformed, forward-looking, and built for impact.<\/p>\n

Statifacts offers subscription services for data and analytics
\ninsights. This page provides options to explore and purchase a subscription
\ntailored to your needs, granting access to valuable statistical resources and
\ntools. Access here – https:\/\/www.statifacts.com\/get-a-subscription<\/b><\/a><\/p>\n

Connect with Us<\/b><\/p>\n

Ballindamm 22, 20095 Hamburg, Germany<\/p>\n

Europe: +44 7383092044<\/b><\/p>\n

Web: <\/b>https:\/\/www.statifacts.com\/<\/b><\/a><\/p>\n

For Latest Update Follow Us: <\/b>https:\/\/www.linkedin.com\/company\/statifacts<\/b><\/a><\/p>\n

Our Trusted Data Partners:<\/b><\/p>\n

Precedence Research<\/b><\/a> | <\/b>Towards Healthcare<\/b><\/a> | <\/b>Nova One Advisor<\/b><\/a><\/p><\/p>\n","protected":false},"excerpt":{"rendered":"According to Statifacts, the worldwide gynecology drugs market size was valued at approximately USD 69.79 billion in 2024…\n","protected":false},"author":2,"featured_media":126193,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[175],"tags":[79,18,19,17,188],"class_list":{"0":"post-126192","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-eire","10":"tag-ie","11":"tag-ireland","12":"tag-markets"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/126192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=126192"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/126192\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/126193"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=126192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=126192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=126192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}